-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on vTv Therapeutics, Maintains $57 Price Target

Benzinga·10/14/2026 10:09:04
BTIG analyst Kambiz Yazdi reiterates vTv Therapeutics (NASDAQ:VTVT) with a Buy and maintains $57 price target.